Isoflupredone Acetate; Neomycin Sulfate; Tetracaine Hydrochloride

Verify with FDA CVM →

78 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
78
Total Reports
9
Deaths Reported
1150.0%
Death Rate

Active Ingredients

Isoflupredone Acetate; Neomycin Sulfate; Tetracaine Hydrochloride

Administration Routes

TopicalUnknownOralAuricular (Otic)Ophthalmic

Species Affected

Dog 53
Unknown 16
Cat 6
Human 3

Most Affected Breeds

Unknown 19
Shih Tzu 5
Retriever - Labrador 4
Retriever - Golden 4
Pug 4
Domestic Shorthair 4
Terrier (unspecified) 3
Chihuahua 3
Mixed (Dog) 2
Shepherd Dog - German 2

Most Reported Reactions

Polydipsia 17
Polyuria 14
Other abnormal test result NOS 11
Lethargy (see also Central nervous system depression in 'Neurological') 9
Diarrhoea 7
Leucocytosis NOS 5
Urinary incontinence 5
Anorexia 5
Vomiting 5
Lack of efficacy - NOS 5
Tubes, Leaking 4
Seal, Abnormal 4

Outcome Breakdown

Ongoing
34 (54.8%)
Recovered/Normal
11 (17.7%)
Outcome Unknown
8 (12.9%)
Died
5 (8.1%)
Euthanized
4 (6.5%)

Data Summary

Metric Value
Total adverse event reports 78
Reports involving death 9
Case-fatality rate (reported events) 1150.0%
Distinct species in reports 4
Distinct breeds in reports 20
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Isoflupredone Acetate; Neomycin Sulfate; Tetracaine Hydrochloride Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 78 adverse event reports referencing Isoflupredone Acetate; Neomycin Sulfate; Tetracaine Hydrochloride, including 9 reports in which the animal died — a 1150.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Isoflupredone Acetate; Neomycin Sulfate; Tetracaine Hydrochloride. Reported administration routes include Topical, Unknown, Oral, Auricular (Otic). These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Isoflupredone Acetate; Neomycin Sulfate; Tetracaine Hydrochloride reports are Dog (53 reports), Unknown (16 reports), Cat (6 reports), with Dog accounting for the largest share. Within those species, Unknown (19), Shih Tzu (5), Retriever - Labrador (4) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Isoflupredone Acetate; Neomycin Sulfate; Tetracaine Hydrochloride are Polydipsia (17), Polyuria (14), Other abnormal test result NOS (11), Lethargy (see also Central nervous system depression in 'Neurological') (9). Of the 62 reports with a coded outcome, Ongoing is the leading category at 54.8%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Isoflupredone Acetate; Neomycin Sulfate; Tetracaine Hydrochloride.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial